[1] de Hoog GS, Guarro J, Gené J,et al. Atlas of Clinical Fungi[M].2nd ed. Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands and Universitat Rovira i Virgili, Reus, Spain,2000. [2] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Approved standard. CLSI documentM38-A2[S]. Clinical and Laboratory Standards Institute,Wayne, PA,2008. [3] Deng S, van den Ende AH, Ram AF, et al.Evolution of CDC42, a putative virulence factor triggering meristematic growth in black yeasts[J]. Stud Mycol,2008,61:121-129. [4] Li RY,Wang DL. Studies on phaeohyphomycosis and its causative agents in China[J]. Jap J Med Mycol,1996, 37(3):135-141. [5] Li DM, de Hoog GS. Cerebral phaeohyphomycosis-a cure at what lengths[J]? Lancet Infect Dis,2009, 9(6):376-383. [6] Kanj SS, Amr SS, Roberts GD. Ramichloridium mackenziei, brain abscess: report of two cases and review of the literature[J]. Med Mycol, 2001,39(1):97-102. [7] 张敏,万哲,余进,等.特比萘芬和伊曲康唑联合应用对暗色孢科真菌的体外药敏试验研究[J].中国真菌学杂志,2007,2(2):78-79. [8] Deng S, de Hoog GS, Badali H,et al.In vitro antifungal susceptibility of Cladophialophora carrionii,an agent of human chromoblastomycosis[J].Antimicrob Agents Chemother,2013,57(4):1974-1977. [9] 孙志坚,李若瑜,万喆,等.产孢丝状真菌药敏试验检测暗色真菌对九种药物的敏感性[J].中华皮肤科杂志,2004,37(4):197-198. [10] Esterre P, Inzan CK, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine:preliminary results of an open pilot study[J]. Br J Dermatol ,1996,134 (Suppl 46): 33-36. |